文献速递脊柱关节炎

司库奇尤单抗治疗银屑病关节炎的5年疗效与安全性:FUTURE 2研究终期结果

Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study.
PubMed 文献 · Lancet Rheumatol · 2020-01-01

FUTURE 2是一项3期双盲安慰剂对照研究,评估司库奇尤单抗300 mg和150 mg治疗活动性银屑病关节炎的5年疗效与安全性。397例患者中248例(62%)完成5年治疗;300 mg组5年ACR20/50/70应答率分别为74%/52%/32%,150 mg组为70%/43%/29%;未发现新的安全性信号。

要点

  • 司库奇尤单抗300 mg和150 mg在5年内维持ACR和PASI应答。
  • 52%的患者在研究期间需要剂量上调。

核心结论

  • 司库奇尤单抗300 mg和150 mg在5年内持续改善银屑病关节炎的体征和症状,安全性一致。

研究设计与样本

  • FUTURE 2为3期双盲安慰剂对照研究,在亚洲、澳大利亚、加拿大、欧洲和美国的76个中心进行。
  • 397例活动性银屑病关节炎患者随机分配至司库奇尤单抗300 mg、150 mg、75 mg或安慰剂组。

主要发现

  • 5年时司库奇尤单抗300 mg组96例可评估患者中ACR20/50/70应答分别为71例(74%)、50例(52%)、31例(32%)。
  • 5年时司库奇尤单抗150 mg组96例可评估患者中ACR20/50/70应答分别为67例(70%)、41例(43%)、28例(29%)。
  • 从150 mg剂量上调至300 mg后第24至32周和第48至84周,ACR和PASI无应答者比例下降,应答者比例上升。

临床怎么用

  • 对于活动性银屑病关节炎患者,可考虑长期使用司库奇尤单抗300 mg或150 mg治疗。
  • 治疗过程中若出现活动性体征,可考虑将150 mg上调至300 mg。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Secukinumab is an interleukin-17A inhibitor used in the treatment of patients with active psoriatic arthritis. In the phase 3 FUTURE 2 trial, secukinumab showed sustained improvement in clinical outcomes over 2 years. Because scarce data exists on the long-term treatment with biological therapies in patients with psoriatic arthritis, we aimed to assess and describe the 5-year (end-of-study) results on the efficacy and safety of secukinumab 300 mg and 150 mg doses, as well as dose escalation, from the FUTURE 2 study. METHODS: FUTURE 2 is a phase 3, double-blind, placebo-controlled study done at 76 centres in Asia, Australia, Canada, Europe, and the USA. Patients with active psoriatic arthritis aged 18 years or older were randomly assigned to either secukinumab (300 mg, 150 mg, or 75 mg) or placebo weekly from baseline and then every 4 weeks from week 4. Secukinumab dose was escalated from 150 mg to 300 mg and from 75 mg to 150 mg or 300 mg starting at week 128, if active signs of disease were observed in patients, on the basis of the physician's assessment, with the escalated dose maintained thereafter. We assessed key efficacy endpoints at week 260 (5 years) for secukinumab 300 mg and 150 mg, including American College of Rheumatology (ACR) and Psoriasis Area and Severity Index (PASI) responses. The safety analysis included all patients who received one or more doses of secukinumab. We report data as observed. This study is registered with ClinicalTrials.gov, NCT01752634. FINDINGS: At randomisation, 65% of patients were naive to tumour necrosis factor inhibitors and 47% were receiving concomitant methotrexate. Of 397 patients randomly assigned in FUTURE 2, 248 (62%) completed 5 years of treatment, including 64 (64%) of 100 patients in the original secukinumab 300 mg group, 65 (65%) of 100 in the 150 mg group, 59 (60%) of 99 in the 75 mg group, and 60 (61%) of 98 in the placebo group. Overall, 127 (52%) of 242 patients required dose escalation during the study. ACR responses at 5 years were 71 (74%; ACR20), 50 (52%; ACR50), and 31 (32%; ACR70) of 96 evaluable patients in the secukinumab 300 mg group, and 67 (70%; ACR20), 41 (43%; ACR50), and 28 (29%; ACR70) of 96 evaluable patients in the secukinumab 150 mg group. From 24 to 32 weeks and from 48 to 84 weeks after dose escalation from secukinumab 150 mg to 300 mg, the proportions of ACR and PASI non-responders decreased, whereas the proportions of ACR and PASI responders increased. During the entire treatment period, the most frequent treatment-emergent serious adverse event was serious infection (exposure-adjusted incidence 1·7, 95% CI 1·1-2·5; n=25) in the any secukinumab group. No new or unexpected safety signals were reported. INTERPRETATION: Secukinumab 300 mg and 150 mg provided sustained improvement in the signs and symptoms of psoriatic arthritis, with consistent safety over 5 years. This study supports the clinical benefit and safety of long-term treatment with secukinumab in patients with psoriatic arthritis. FUNDING: Novartis.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. McInnes IB, Mease PJ, Kivitz AJ, et al. Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study. Lancet Rheumatol. 2020. PMID: 38268157. doi:10.1016/S2665-9913(20)30036-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。